A biotechnology executive in the field of clinical research, Raj Prabhakar has dedicated nearly two decades to the industry. Raj Prabhakar most recently led liver cancer programs at Celsion - EGEN, and currently partners cell therapy programs for Caladrius Biosciences.
Hepatocellular carcinoma (HCC) is among the deadliest forms of primary liver cancer. Each year, 26,000 new cases are diagnosed in the United States. Worldwide, the population reaches 750,000. Individuals with hepatitis B or C have a higher likelihood of developing the condition. By 2020, the World Health Organization predicts HCC will be the most common form of cancer.
In response to these statistics, Celsion is conducting clinical trials for a product called ThermoDox. It uses radio-frequency ablation (RFA) to release doxorubicin, a type of anthracycline chemotherapy, in targeted regions affected by cancer cells. ThermoDox creates thermal zones in the liver that expand the treatment area, thus providing the ability to destroy micrometastases. The Phase III clinical trial includes 550 patients. A Phase II study is also underway to evaluate the effectiveness of ThermoDox in recurrent chest-wall breast cancer.
Hepatocellular carcinoma (HCC) is among the deadliest forms of primary liver cancer. Each year, 26,000 new cases are diagnosed in the United States. Worldwide, the population reaches 750,000. Individuals with hepatitis B or C have a higher likelihood of developing the condition. By 2020, the World Health Organization predicts HCC will be the most common form of cancer.
In response to these statistics, Celsion is conducting clinical trials for a product called ThermoDox. It uses radio-frequency ablation (RFA) to release doxorubicin, a type of anthracycline chemotherapy, in targeted regions affected by cancer cells. ThermoDox creates thermal zones in the liver that expand the treatment area, thus providing the ability to destroy micrometastases. The Phase III clinical trial includes 550 patients. A Phase II study is also underway to evaluate the effectiveness of ThermoDox in recurrent chest-wall breast cancer.